1. Scrip
  2. >>Business
  3. >>Deals

EY: Don’t Expect Mega-Mergers To Return, But ‘Never Say Never’

EY Predicts Continued Emphasis On Bolt-On Deals, Partnerships In 2022

 
• By Joseph Haas

Firm’s annual biopharma firepower report notes there were no mega-mergers in 2021 and the conditions continue to make smaller deals and partnerships a better risk proposition.

Mergers
Expect another down year for major M&A, EY report predicts

Looking ahead, Ernst & Young expects the biopharmaceutical industry to continue the emphasis on partnerships and bolt-on acquisitions over company acquisitions seen in 2021, only perhaps at greater volume. The rationale for partnerships and bolt-ons simply is better than for large-scale M&A as biopharmas look to bolster their pipelines and portfolios against expected mid-decade patent cliff issues that are expected to drive down compound annual growth rates, the firm’s 2022 EY M&A Firepower Report asserts.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.